Strategic Growth Calyx, formerly LIQUENT, is a specialized eClinical and regulatory solutions provider with revenue in the 50-100 million range and a growing footprint evidenced by recent acquisitions and partnerships. Target potential upsell opportunities in clinical data management, imaging biomarkers, and regulatory submissions to expand project scopes with current pharma clients.

Imaging & Biomarkers Recent acquisition of Invicro and ongoing work in quantitative imaging biomarkers position Calyx to upsell advanced imaging analytics, RTSM/IRT capabilities, and biomarker strategy services to drug sponsors pursuing precision medicine and complex trial designs.

Clinical Supply Launch of Calyx Supply Simulation demonstrates appetite for specialized forecasting and supply planning services. Generate cross-sell around forecasting accuracy, supply chain risk mitigation, and trial logistics optimization for ongoing and future clinical trials.

Broad Tech Stack Stack includes Azure API Apps, Qlik, Tableau, Informatica, and JavaScript with Microsoft Exchange, suggesting opportunities to modernize client analytics platforms, integrate real-time data dashboards, and optimize data workflows for trial performance metrics.

Expansion & Partnerships Evidence of strategic partnerships and geographic expansion (Nottingham, Morrisville) indicates readiness for targeted BD efforts in North America and Europe, with potential to bundle services across eClinical, regulatory, imaging, and neuro/psychiatric research collaborations.